

# Formulary Announcement



SASKATCHEWAN

effective June 1, 2021

Now listed on the Saskatchewan Drug Plan under The Exception Drug Status (EDS) Program. [Click here](#) for more information on HULIO<sup>®</sup> indications and EDS criteria.

# HULIO<sup>®</sup>

A biosimilar of HUMIRA<sup>®</sup>

## IMPORTANT INFORMATION

Product	DIN	Pack Size	Viatriis Code	UPC
Hulio <sup>®</sup> 40 mg/0.8 mL prefilled syringe	02502399	2	400553108	055873101040
Hulio <sup>®</sup> 40 mg/0.8 mL prefilled pen	02502402	2	400553121	055873101057

**Available to order now!**

For more information contact your Viatriis representative or Viatriis Customer Service at 1-800-575-1379.

HUMIRA<sup>®</sup> is a product of AbbVie Corporation.

BGP Pharma ULC, a Viatriis Company 85 Advance Road, Etobicoke, Ontario Tel. 1-800-575-1379 Fax: 1-888-745-7373

HUL-2021-0231E – MA2021